Indivior Pharmaceuticals (INDV) CAO receives stock and performance unit awards

Rhea-AI Filing Summary

Indivior Pharmaceuticals, Inc. reported that Chief Accounting Officer Anderson Woodrow D acquired company equity through compensation awards. He received 6,903 shares of common stock at a price of $0, bringing his directly held common stock to 11,293 shares.

He was also granted 23,975 performance stock units at $0, following certification of performance conditions on February 9, 2026. These performance-based awards are scheduled to vest on March 3, 2026, subject to continued employment, while the restricted stock units vest in three equal annual installments beginning February 10, 2027.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Anderson Woodrow D

Role Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,903	$0.00	--
Grant/Award	Performance Stock Units	23,975	$0.00	--

Holdings After Transaction: Common Stock — 11,293 shares (Direct); Performance Stock Units — 23,975 shares (Direct)

Footnotes (1)

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer. On March 3, 2023, the Reporting Person was granted a conditional award for 23,975 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anderson Woodrow D

(Last) (First) (Middle)

10710 MIDLOTHIAN TURNPIKE

SUITE 125

(Street)

NORTH CHESTERFIELD VA 23235

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Indivior Pharmaceuticals, Inc. [ INDV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		A		6,903(1)	A	$0	11,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Units	$0	02/09/2026		A		23,975		03/03/2026(2)	(2)	Common Stock	23,975	$0	23,975	D

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock, vesting in three equal annual installments beginning on February 10, 2027, the first anniversary of the grant, subject to the Reporting Person's continued service with the Issuer.

2. On March 3, 2023, the Reporting Person was granted a conditional award for 23,975 shares, subject to satisfaction of performance conditions, which were certified on February 9, 2026. The award vests, subject to continued employment conditions, on March 3, 2026.

Remarks:

Exhibit 24 Power of Attorney

	/s/Alice Givens, Power of Attorney	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Indivior Pharmaceuticals (INDV) report for Anderson Woodrow D?

Indivior Pharmaceuticals reported that Chief Accounting Officer Anderson Woodrow D received equity awards. He acquired 6,903 shares of common stock at $0 and 23,975 performance stock units, both as part of his compensation, rather than open-market purchases or sales.

How many Indivior (INDV) common shares does Anderson Woodrow D hold after this Form 4?

After the reported award, Anderson Woodrow D beneficially owns 11,293 shares of Indivior common stock directly. This figure reflects the addition of 6,903 newly granted shares, given as equity compensation at no cash cost to him.

What performance stock units were granted to the Indivior (INDV) Chief Accounting Officer?

The Chief Accounting Officer received 23,975 performance stock units at a price of $0. These units were originally conditionally awarded in 2023, with performance conditions later certified on February 9, 2026, converting into a vested schedule subject to continued employment.

When do the Indivior (INDV) performance stock units for Anderson Woodrow D vest?

The 23,975 performance stock units are scheduled to vest on March 3, 2026. Vesting depends on continued employment, following certification of the underlying performance conditions on February 9, 2026, as described in the equity award footnotes.

How do the restricted stock units granted by Indivior (INDV) vest over time?

The restricted stock units vest in three equal annual installments. Vesting begins on February 10, 2027, the first anniversary of the grant date, and continues annually, provided Anderson Woodrow D remains in service with Indivior Pharmaceuticals throughout the vesting period.

Were the Indivior (INDV) insider awards reported as purchases or compensation grants?

The awards were reported as compensation grants, not market purchases. The Form 4 uses transaction code “A” for grant, award, or other acquisition, and both the common stock and performance stock units carried a $0 price, indicating equity compensation.